Overview

A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy

Status:
Completed

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

Summary

A medical research study in adult patients who have moderate to severe Crohn's disease designed to determine whether or not treatment with an experimental drug called ustekinumab (or CNTO1275) is safe or not and to determine if the treatment will reduce the symptoms of Crohn's disease.

Phase:

Phase 2

Details

Lead Sponsor:

Centocor, Inc.

Treatments:

Ustekinumab